<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="NEW YORK, NY / ACCESSWIRE / April 5, 2020 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.” data-reactid=”12″>NEW YORK, NY / ACCESSWIRE / April 5, 2020 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Jeld-Wen Holding, Inc. (JELD)” data-reactid=”13″>Jeld-Wen Holding, Inc. (JELD)
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/jeld-wen-holding-inc-loss-submission-form?prid=5915&wire=1
Lead Plaintiff Deadline: April 20, 2020
Class Period: January 26, 2017 to October 15, 2018″ data-reactid=”14″>If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/jeld-wen-holding-inc-loss-submission-form?prid=5915&wire=1
Lead Plaintiff Deadline: April 20, 2020
Class Period: January 26, 2017 to October 15, 2018
Allegations against JELD include that: (1) the Company’s products, including doors, did not compete against other manufacturers on price, contrary to Jeld-Wen’s representations; (2) the market in which the Company sells its doors is not “highly competitive” as the Company claimed; (3) Jeld-Wen’s strong margins and anticipated margin growth were not, as the Company claimed, attributed to changes they had made in Jeld-Wen’s business operations and strategies; and (4) Jeld-Wen failed to disclose the Company’s anti competitive conduct. Because of the foregoing, Defendants’ statements about the Company’s business, operations and prospects lacked a reasonable basis.
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Tilray, Inc. (TLRY)” data-reactid=”16″>Tilray, Inc. (TLRY)
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/tilray-inc-loss-submission-form?prid=5915&wire=1
Lead Plaintiff Deadline: May 5, 2020
Class Period: January 15, 2019 to March 2, 2020″ data-reactid=”17″>If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/tilray-inc-loss-submission-form?prid=5915&wire=1
Lead Plaintiff Deadline: May 5, 2020
Class Period: January 15, 2019 to March 2, 2020
Allegations against TLRY include that: (i) the purported advantages of the marketing and revenue sharing agreement with Authentic Brands Group (the “ABG Agreement”)were significantly overstated; (ii) the under performance of the ABG Agreement would foreseeably have a significant impact on the Company’s financial results; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Inovio Pharmaceuticals, Inc. (INO)” data-reactid=”19″>Inovio Pharmaceuticals, Inc. (INO)
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/inovio-pharmaceuticals-inc-loss-submission-form?prid=5915&wire=1
Lead Plaintiff Deadline: May 12, 2020
Class Period: February 14, 2020 to March 9, 2020″ data-reactid=”20″>If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/inovio-pharmaceuticals-inc-loss-submission-form?prid=5915&wire=1
Lead Plaintiff Deadline: May 12, 2020
Class Period: February 14, 2020 to March 9, 2020
According to a filed complaint, throughout the class period, defendants made misleading statements about the company’s development of a purported vaccine for the novel coronavirus, artificially inflating the company’s share price and resulting in significant investor losses.
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="To learn more contact Vincent Wong, Esq. either via email [email protected] or by telephone at 212.425.1140.” data-reactid=”22″>To learn more contact Vincent Wong, Esq. either via email [email protected] or by telephone at 212.425.1140.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]” data-reactid=”24″>CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]
<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="SOURCE: The Law Offices of Vincent Wong” data-reactid=”25″>SOURCE: The Law Offices of Vincent Wong
View source version on accesswire.com:
https://www.accesswire.com/583948/SHAREHOLDER-ALERT-JELD-TLRY-INO-The-Law-Offices-of-Vincent-Wong-Reminds-Investors-of-Important-Class-Action-Deadlines
Add Comment